[1]李 霞,刘小红,杨 乐.不同年龄阶段癫痫患儿奥卡西平 活性代谢产物血药浓度的临床价值[J].现代检验医学杂志,2015,30(01):143-144.[doi:10.3969/j.issn.1671-7414.2015.01.043]
　LI Xia,LIU Xiao-hong,YANG Le.Clinical Values of Blood Serum Concentration of MHD in Children with Epilepsy of Different Ages[J].Journal of Modern Laboratory Medicine,2015,30(01):143-144.[doi:10.3969/j.issn.1671-7414.2015.01.043]
点击复制

不同年龄阶段癫痫患儿奥卡西平 活性代谢产物血药浓度的临床价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年01期
页码:
143-144
栏目:
检验与临床
出版日期:
2015-01-30

文章信息/Info

Title:
Clinical Values of Blood Serum Concentration of MHD in Children with Epilepsy of Different Ages
文章编号:
1671-7414(2015)01-143-03
作者:
李 霞1; 刘小红1; 杨 乐2
1西安交通大学第一附属医院儿科,西安 710061;
2.西安市儿童医院神经内科,西安 710003
Author(s):
LI Xia1; LIU Xiao-hong1; YANG Le2
1.Department of Pediatrics, the First Affiliated Hospital in Xi'an Jiaotong Uniuersity,Xi'an 710061,China;
2.Department of Neurology,Xi'an Children's Hospital,Xi'an 710003,China
关键词:
奥卡西平;  代谢产物;  血药浓度;  癫痫;  年龄
分类号:
R742.1; R969
DOI:
10.3969/j.issn.1671-7414.2015.01.043
文献标志码:
A
摘要:
目的 探讨年龄因素对癫痫患儿奥卡西平代谢产物血药浓度的影响。方法 将200例患儿按年龄分为四个研究组,A组:<3岁婴幼儿,B组:3～6岁学龄前期儿童,C组:7～13岁学龄期儿童,D组:14～18岁青少年,每个研究组50例患儿; 采用高效液相色谱法对奥卡西平活性代谢产物(MHD)血清稳态血药浓度测定,分析年龄因素与其血药浓度关系。结果 奥卡西平活性代谢产物(MHD)稳态血药浓度随着年龄增长有上升趋势,但差异无统计学意义(P>0.05)。结论 奥卡西平血清MHD浓度在癫痫患儿中个体差异较大,应在服用过程中动态监测血药浓度,及时调整用药剂量,促进给药方案个体化实施。
Abstract:
Objective To investigate effects of blood serumconcentration of MHD in children with epilepsy of different ages.Methods Two hundred children with epile psy were divided into four groups according to age,group A:<3 years old infants; group B:3～6 years old preschoolers; group C:7～13 years old school-age chidren.Group D:14～18 years old adolescents,each group had 50 chidren.The serum concentration of active metabolite was detected by high-perform ance liquid chromatography(HPLC)method.Results The serum concentration of MHD increase with age,but there were no statistical significance(P>0.05).Conclusion The indiv idual variation in blood serum concentrations of MHD inchildren with epilepsy adminisered with oxcarbazepine is high,therefore monitoring the blood serum concentration is helpful to adjust the dose of medication and to promote the implementation of the individualized dosing regimens.

参考文献/References:

[1] 尹艳秋,蔡 婧,闫丹丹,等.奥卡西平治疗小儿癫痫87例[J].医药导报,2012,31(5):603-605.
[2] 王红梅,吴沪生,陈春红,等.奥卡西平单药治疗儿童部分性癫痫疗效和安全性观察[J].中国实用儿科杂志,2012,27(3):214-217. Wang HM,Wu HS,Chen CH,et al.The clinical efficacy and safety of oxcarbazepine monotherapy for children with newly diagnosed partial epilepsy[J].
[3] 陈其钻,陈谦学,郭振涛,等.奥卡西平单药治疗癫痫疗效及耐受性的Meta分析[J].卒中与神经疾病,2012,19(5):283-287.
[4] 袁文林,王立阳.奥卡西平治疗儿童癫痫部分性发作的临床观察[J].当代医学,2012,18(31):110-111.
[5] Theodor W May,Elisabeth Korn-Merker,Bernhard Ra-mbeck.Clinical Pharmacokinetics of Oxcarbazepine[J].Clin Pharmcokinet,2003,42(12):1023-1042.
[6] Kothare SV,Khurana DS,Mostofi N,et al.Oxcarbazepine monotherapy in children and adolescents:a single-center clinical experience[J].Pediatr Neurol,2006,35(4):235-239.
[7] Flesch G.Overview of the clinical pharmacokinetics of oxcarbazepine[J].Clin Drug Investig,2004,24(4):185-203.
[8] Bring P,Ensom MH.Does oxcarbazepine warrant the-rapeutic drug monitoring A critical review[J].Clin Pharmacokinet,2008,47(12):767-778.
[9] Johannessen SI,Battino D,Berry DJ,et al.T Therapeutic drug monitoringof the newer antiepileptic drugs[J].Ther Drug Monit,2003,25(3):347-363.
[10] Neds HM,Sierens AC,Naelaerts K,et al.Therapeutic drug monitoring of old and newer antiepileptic drugs[J].Clin Chem Lab Med,2004,42(11):1228-1255.
[11] Bouquie R,Dailly E,Bentue-Ferrer D.Therapeutic drug monitoring of oxcarbazepine [J].Therapie,2010,65(1):61-65.
[12] Agarwal NB,Agarwal NK,Mediratta PK,et al.Ef-fect of lamotrigine,oxcarbazepine

相似文献/References:

[1]王 磊,孙文利,刘 瑞,等.HPLC-MS/MS法检测骨髓移植患者全血环孢素A(CsA)浓度及与AM1和AM4N代谢产物的相关性研究[J].现代检验医学杂志,2019,34(02):52.[doi:10.3969/j.issn.1671-7414.2019.02.014]
　WANG Lei,SUN Wen-li,LIU Rui,et al.Correlation of the Concentration of Whole Blood Cyclosporine A(CsA)Detected by HPLC-MS/MS Method and Metabolites of AM1and AM4N in Bone Marrow Transplant Patients[J].Journal of Modern Laboratory Medicine,2019,34(01):52.[doi:10.3969/j.issn.1671-7414.2019.02.014]

备注/Memo

备注/Memo:

通讯作者:刘小红,Tel:029-85323824 E-mail:liuxiaoh@mail.xjtu.edu.cn。
更新日期/Last Update: 2015-01-30